Advertisement

However, the company noted that the results have yet to achieve statistical significance, the Associated Press reported. A final analysis of the data from the trial won't be completed until early 2006.

The Oncophage vaccine is a personalised treatment that utilises tissue from a malignant tumour to instruct a patient's immune system to attack the cancer, the AP reported.

This study included 322 people with advanced skin cancer that had spread to other areas of the body. The patients received either Oncophage or standard therapies, including chemotherapy, surgery, biological agents, or a combination of those treatments.

The patients who received Onchophage lived an average of 20.9 months, compared to an average of 12.8 months for patients who received standard treatment, the AP reported. – (HealthDayNews)

Visit our Skin Centre for more information.

October 2005
 

Print this article on

Rate this article Poor 1 2 3 4 5 Excellent

JOBS

Operations Manager R20,000-25,000 Per Month Cost To Company Incl Benefits Gauteng - East Rand Financial Accountant: CA(SA) R400,000-500,000 Per Annum Cost To Company Gauteng - Johannesburg Key Account Manager Gauteng Java Developer-CT Western Cape - Cape Town Java Developer-Jozi Gauteng Account Manager R460,000-540,000 Per Annum Cost To Company Plus Benefits Gauteng Account Manager R460,000-540,000 Per Annum Market Related Plus Benefits South Africa Case Manager R210,000-220,000 Per Annum Negotiable Gauteng - Pretoria Find more jobs Register your CV Post a job